SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.

J Cardiovasc Dev Dis · 2023 · PMC10455499 · PMID 37623335

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the CV death and urgent visit for heart failure, while tending to a decrease in the empagliflozin group, did not reach statistical significance with HRs of (0.88; 95% CI, 0.74–1.05) and (0.76; 95% CI, 0.55–1.07), respectively.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.